Companies · Biotechnology

Ultivue, Inc.

CAMBRIDGE · Biotechnology

Diligence memoA one-page analyst read on Ultivue, Inc. — recommendation, valuation, rhythm, risks.
$55.2M
Total raised · real
4
Rounds
0.1×
Latest step-up
Top 18%
Sector rank · raised
Series B
Latest stage · inferred · Thu Jul 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Ultivue, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.14× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Quiet
  • Last raise 24 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Ultivue, Inc. is one of 4291 Biotechnology companies tracked from CAMBRIDGE. By capital raised it ranks in the upper tier (ahead of 83% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2024-07-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2015-08-07 Raised $5.2M (real) Modeled valuation $186M (est)$5.2M$186MSeries A2015Series A · 2017-07-06 Raised $10M (real) Modeled valuation $365M (est)$10M$365MSeries A2017Series B · 2017-07-06 Raised $20M (real) Modeled valuation $804M (est)$20M$804MSeries B2017Series B · 2019-06-13 Raised $27M (real) Modeled valuation $1.1B (est)$27M$1.1BSeries B2019Series B · 2024-07-11 Raised $3.3M (real) Modeled valuation $23M (est)$3.3M$23MSeries B2024+$10M+$20M+$27M+$3.3MCumulative $65M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.2M · 2015
Series A extension$10.1M · 2017
Series B$20.2M · 2017
Series B extension$26.5M · 2019
Series B extension$3.3M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$23.4M
Base estimate est.
$6.6M
Conservative case
$41.7M
Upside case
$18.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $186.2M · 2015-08-072015Series A · modeled $365.2M · 2017-07-06Series B · modeled $803.7M · 2017-07-06Series B · modeled $1.1B · 2019-06-13Series B · modeled $23.4M · 2024-07-112024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
27 mo
Avg between rounds
$6.2M/yr
Capital velocity
10.9 yr
On record since
2015
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.7× above median
This company$55.2M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.2× of median
This company$3.3M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$23.4M
Sector median$64.2M

Raised more than 83% of sector peers (real $). Modeled value above 31% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #180 of 197.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $737.5M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $617.6M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.1M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $590.7M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $569.5M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $553.9M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.2M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.0M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.0M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $491.7M (est)Ultivue, Inc. (this company) Raised $55.2M · modeled $23.4M (est)Ultivue, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$737.5M4.41×
YAP Therapeutics IncSeries B$30.1M$617.6M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.1M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$590.7M3.53×
EpiBiologics, Inc.Series B$30.0M$569.5M3.40×
GIOGI LtdSeries B$27.3M$553.9M3.31×
SonoThera, Inc.Series B$30.4M$550.2M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.0M3.25×
GIOHEALTH LtdSeries B$24.5M$498.0M2.97×
GIOCAN LtdSeries B$24.5M$498.0M2.97×
GIODIA LtdSeries B$24.5M$498.0M2.97×
Cerapedics IncSeries B$99.1M$491.7M2.94×
Ultivue, Inc. this companySeries B$55.2M$23.4M0.14×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.2M2015-08-07$23.4M$186.2M85%
Series A$10.1M2017-07-06$45.9M$365.2M90%
Series B$20.2M2017-07-06$112.5M$803.7M90%
Series B$26.5M2019-06-13$147.2M$1.1B90%
Series B$3.3M2024-07-11$18.5M$23.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.2M2015-08-07
    • First recorded raise — entered as Series A.
    • 6 investors on this round.
  2. Series A$10.1M2017-07-06
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 6 investors on this round.
  3. Series B$20.2M2017-07-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 11 investors on this round.
  4. Series B$26.5M2019-06-13
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 14 investors on this round.
  5. Series B$3.3M2024-07-11
    • Raised again after 61 mo — slower than the ~14 mo sector norm.
    • Round 8.0× smaller than the prior — bridge or down round.
    • 5 investors on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~27mo cadence
$3.3M
Modeled next size est.range $3.3M$5.3M
0.1×
Last step-up
$6.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Keith Crandell10 other2017-07
Andrea Jackson5 other2024-07
David R. Walt4 other2015-08
Fenel Eloi2 other2024-07
Michael Natan2 other2017-07
Peng Yin2 other2017-07
Robert Carson2 other2024-07
Andrew Stevenson1 other2017-07
Lian Yong Chen2017-07
Peng R. Ying2015-08
Sharon Yong Kedar2019-06
Wen R. Chen2017-07
Registry & provenance

Ultivue, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1651511
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Vizgen, Inc.BiotechnologySeries D+$295.1M$319.9Mnetwork3 shared operators · same sector
Spear Bio Inc.BiotechnologySeries C$50.1M$391.9Mnetwork2 shared operators · same sector
Torus Biosystems, Inc.BiotechnologySeries B$28.9M$706.3Mnetwork1 shared operator · same sector · same stage
Arbor Biotechnologies, Inc.BiotechnologySeries D+$230.6M$5.7Bnetwork2 shared operators · same sector
Boreal Genomics Inc.BiotechnologySeries B$24.5M$714.4Mnetwork1 shared operator · same sector · same stage
Acer Therapeutics Inc.BiotechnologySeries B$52.2M$21.1Msame sector · same stage
Inceptor Bio, LLCBiotechnologySeries B$59.6M$18.5Msame sector · same stage
Superluminal Medicines, Inc.BiotechnologySeries B$50.7M$22.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
uLab Systems, Inc.BiotechnologySeries C$2.8B88%
U1 Bio, Inc.BiotechnologySeries A$136.3M84%
Ubivac, Inc.BiotechnologySeed$758K83%
Arcellx, Inc.BiotechnologySeries D+$1.8B83%
Rion LLCBiotechnologySeries B$693.5M82%
ARC Medical Inc.BiotechnologySeed$6.3M82%
Ntxbio, LlcBiotechnologyPre-Seed$50.5M82%
Urolution Medical Inc.BiotechnologyPre-Seed$852K82%
Frequently asked
How much funding has Ultivue, Inc. raised?
Ultivue, Inc. has raised approximately $55.2M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Ultivue, Inc.'s estimated valuation?
Provath's modeled valuation for Ultivue, Inc. is approximately $23.4M (modeled range $6.6M–$41.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Ultivue, Inc. at?
Ultivue, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Jul 11.
What does Ultivue, Inc. do and where is it based?
Ultivue, Inc. operates in the Biotechnology sector, based in CAMBRIDGE.
Explore related

See where Ultivue, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ultivue, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.